Never Stop Bioteching

Biotech trials grow more decentralized, diverse, and dynamic by the day. To keep pace with change, the biotech development process needs to evolve as well. So we redesigned the journey around the patient. By pairing a highly configurable development platform with biotech teams who have the expertise and experience to anticipate and adapt throughout development, we can help you deliver on your mission to always put patients first. We call it Bioteching – and it's redefining development every step of the way.


Watch now

Project Optimus: Early-stage haste can lead to waste

The study designs and dose selection strategies that have supported decades of oncology drug development are now crumbling as the FDA’s Project Optimus takes full effect. The agency is now scrutinizing Phase 1 and 2 studies to see whether they pinpoint the dose that is biologically effective and maintains a truly acceptable safety profile. The added time and cost to achieve this objective will pay off in products with a defined risk-benefit profile, smoother regulatory path, better long-term patient adherence, and improved quality of life. In turn, this will sustain uptake and market share. In this webinar, we will share several techniques, which we’ve found in our work with clients that can help companies achieve this new standard.



No matter what you’re innovating, we can help your biotech company navigate competitive, regulatory, and reimbursement landscapes while innovating and streamlining your development plan. Learn more about Parexel Biotech solutions.

Explore our solutions

We are always available for a conversation.